Patent 12123002 was granted and assigned to Voyager Therapeutics on October, 2024 by the United States Patent and Trademark Office.
The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.